Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Accelerating the development, equitable access to, and stewardship of new antibiotics is critical to protect public health and address antimicrobial resistance (AMR). To understand and assess how the current antibiotics innovation sub-system – or ‘niche’ – addresses this task, we reviewed the literature, compiled and analyzed a database of 211 antibiotic developers, and conducted 10 stakeholder interviews.
1. Introduction The hepatitis C virus (HCV) poses a significant public health challenge globally. According to the World Health Organization (WHO), an estimated 50 million people are living with chronic hepatitis C infection worldwide, with about 1 million new infections occurring per year [1]. Despite advancements in prevention and treatment, hepatitis C remains a leading cause of liver-related morbidity and mortality, with an estimated 244,000 deaths in 2022 [1].
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.